EU Pharmacovigilance Regulation 2025/1466: Key Changes and Impact for MAHs

Amending Implementing Regulation (EU) No 520/2012, the update reflects today’s digital, data-driven PV environment and introduces clearer expectations around oversight, transparency, and risk-based governance. For Marketing Authorisation Holders (MAHs), the regulation brings immediate operational implications, particularly across signal management, QPPV oversight, quality systems, and third-party governance.

 

 

Stronger QPPV Oversight and System Governance

The regulation reinforces the QPPV’s central role in ensuring continuous oversight of the pharmacovigilance system. Requirements for organisational transparency, clearer documentation of where key PV activities are performed, and tighter control of deviations place increased emphasis on effective QPPV governance rather than administrative volume.

Updates to the Pharmacovigilance System Master File (PSMF) now focus on major and critical deviations only, reducing unnecessary burden while maintaining inspection readiness—provided that QPPVs can demonstrate robust control and traceability.

 

Signal Management: EudraVigilance at the Core

From August 2025, MAHs must routinely monitor EudraVigilance alongside all other relevant data sources. Standalone signal notifications to the EMA are no longer required. Instead, signal evaluation is fully embedded in PRAC-led processes, with MAHs expected to integrate EudraVigilance data into cumulative reviews and regulatory responses.

This shift requires strong alignment between QPPVs, signal management teams, and data workflows, ensuring timely confirmation and assessment of validated signals.

 

 

Greater Accountability Across the Product Lifecycle

The regulation strengthens expectations across several core PV activities:

• PSURs must now document not only the effectiveness of risk-minimisation measures, but also how those measures are implemented in practice.
• PASS transparency is expanded, with mandatory registration, protocol submission before data collection, and timely final report summaries in the EMA register.
• ICSR standards are refined to improve consistency, traceability, and scientific quality, particularly for literature cases.

Collectively, these changes reinforce the need for end-to-end safety oversight, coordinated under the QPPV framework.

 

Enhanced Oversight of Outsourced PV Activities

MAHs retain full responsibility for pharmacovigilance activities performed by third parties. Regulation (EU) 2025/1466 strengthens requirements for vendor governance, including clear role definitions, audit rights, and inspection readiness. Subcontracting chains must be fully controlled, with no further delegation permitted without MAH approval.

Risk-based PV audits—both internal and external—are now explicitly embedded in the regulatory framework, increasing the strategic importance of audit planning and execution.

 

What MAHs Should Be Doing Now

MAHs should already be initiating change control to assess the impact of the regulation on their PV systems, service providers, and governance models. This includes reviewing signal management processes, QPPV oversight structures, PSMF content, PSUR templates, audit strategies, and training programmes. Further clarification is expected through updated GVP Modules in 2026.

 

 

How PrimeVigilance Supports MAHs

PrimeVigilance supports MAHs in translating Regulation (EU) 2025/1466 into practical, inspection-ready pharmacovigilance systems. Our QPPV services, signal management expertise, PV audits, PSUR and PASS support, and vendor oversight frameworks are designed to help sponsors maintain control, demonstrate compliance, and protect patients across the product lifecycle.